About Us
Inpharmus serves as the bridge between global originators and the complex, high-potential MERAT region (Middle East, Russia, North Africa, Türkiye), increasing the treatability of oncology and rare diseases.
Inpharmus serves as the bridge between global originators and strategically complex yet high-potential MERAT region (Middle East, Russia, North Africa, Türkiye), accelerating patient access to life-changing oncology and rare disease treatments.We address a fundamental market gap by connecting innovation with patients in need, while making MERAT more accessible, more navigable, and better served.
To originator partners, we provide a reliable, evidence-driven expertise across all stakeholders in MERAT, ensuring that their products are managed with the highest standards of safety, compliance, and operational precision.
We elevate the visibility and reputation of MERAT within the global oncology and rare disease circles. Through our differentiated “Speed & Star” approach, we place HCPs at the center by recognizing them as pivotal actors and elevating them as true “Stars” throughout their journey with Inpharmus.
Our 2030 Ambition: Becoming a Unicorn
Inpharmus will become by far the most trusted and convenient partner in the MERAT with a focus on Oncology and Rare Diseases through our differentiated HCP engagement. By 2030, our ambition is to:
✦ Becoming a unicorn with achieving 1B+ valuation
✦ Be the #1 partner in HCP satisfaction across MERAT
✦ Operate with a focused, selective high-value portfolio products across MERAT with a strong focus in Türkiye, Russia, KSA
We are the only pharma company with the operational capability to commercialize innovative treatments in onco and rare diseases in MERAT.
Our Differentiated Value
Our differentiated value is Speed & Star experience to our limited customer base

Speed

Star
We provide speed in 5 Levers

Treatment Supply Time

Days to Market Access

Time to Sign Deal for FDA/EMA approved Innovative Products

HCP's Medical Information Access Time

Response Time to HCP Requests
Star Treatment = Know Your HCP (KYH) x Create Special (CS)

Know Your HCP (KYH)

Create Special (CS)
Our Culture
Our culture is defined by the way we work each day. As a learning organization, we continuously refine our practices through disciplined reflection, systematic improvement, and a commitment to operational excellence. This approach enables us to better support the healthcare community and the complex therapeutic areas in which we operate.
At the center of our culture is the community we serve: leading HCPs in oncology and rare diseases, originator partners, and key decision makers. Operating in markets where relationships and systems hold equal importance, we prioritize trust, clarity, and consistency. We demonstrate this through Star Treatment, a principle rooted in respect and care, and Fast Service, our commitment to timely, coordinated, and reliable execution.
Delivering at this level requires A-Players. These are professionals who drive high performance, embody our cultural values, and bring core capabilities such as initiative, accountability, collaboration, effective communication, and a growth mindset. For those in leadership, additional expectations include people development and the ability to guide vision and change. We recruit and develop talent with these qualities in mind.
We advance through momentum. Momentum begins with ambitious goals, strengthened by disciplined follow-through, clear measurement, and continuous learning. We recognize that challenges and errors are part of progress; what matters is learning, adapting, and improving with each step.
By upholding these principles collectively, we create an environment where progress is visible, performance is sustained, and meaningful impact becomes achievable. Our culture is a shared responsibility, shaped and strengthened by all of us.
Our Markets
Inpharmus is a pharmaceutical company that specialises in enabling access to innovative treatments for 350 million people living in major emerging markets
Inpharmus is dedicated to advancing innovation across carefully targeted therapeutic areas, leveraging its expertise to develop and distribute treatments to improve patient outcomes.
